ADAR1 Transcriptome editing promotes breast cancer progression through the regulation of cell cycle and DNA damage response.
Breast cancer
DNA damage response
Proliferation
RNA editing
RNA stability
Journal
Biochimica et biophysica acta. Molecular cell research
ISSN: 1879-2596
Titre abrégé: Biochim Biophys Acta Mol Cell Res
Pays: Netherlands
ID NLM: 101731731
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
27
10
2019
revised:
17
03
2020
accepted:
03
04
2020
pubmed:
11
4
2020
medline:
27
10
2020
entrez:
11
4
2020
Statut:
ppublish
Résumé
RNA editing has emerged as a novel mechanism in cancer progression. The double stranded RNA-specific adenosine deaminase (ADAR) modifies the expression of an important proportion of genes involved in cell cycle control, DNA damage response (DDR) and transcriptional processing, suggesting an important role of ADAR in transcriptome regulation. Despite the phenotypic implications of ADAR deregulation in several cancer models, the role of ADAR on DDR and proliferation in breast cancer has not been fully addressed. Here, we show that ADAR expression correlates significantly with clinical outcomes and DDR, cell cycle and proliferation mRNAs of previously reported edited transcripts in breast cancer patients. ADAR's knock-down in a breast cancer cell line produces stability changes of mRNAs involved in DDR and DNA replication. Breast cancer cells with reduced levels of ADAR show a decreased viability and an increase in apoptosis, displaying a significant decrease of their DDR activation, compared to control cells. These results suggest that ADAR plays an important role in breast cancer progression through the regulation of mRNA stability and expression of those genes involved in proliferation and DDR impacting the viability of breast cancer cells.
Identifiants
pubmed: 32275931
pii: S0167-4889(20)30074-4
doi: 10.1016/j.bbamcr.2020.118716
pii:
doi:
Substances chimiques
RNA, Messenger
0
RNA-Binding Proteins
0
ADAR protein, human
EC 3.5.4.37
Adenosine Deaminase
EC 3.5.4.4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
118716Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest RA, RAs, PP, EAS, AB, AIS and PR were Pfizer Chile employees.